Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Solid Biosciences stockholders approve acquisition of AavantiBio » 16:21
12/01/22
12/01
16:21
12/01/22
16:21
SLDB

Solid Biosciences

$6.66 /

-0.03 (-0.45%)

Solid Biosciences…

Solid Biosciences announced the results of the special meeting of the stockholders held on December 1. At the special meeting, Solid's stockholders voted in favor of all proposals, including the proposal to issue shares of Solid's common stock to stockholders of AavantiBio in connection with the acquisition of AavantiBio pursuant to the agreement and plan of merger dated September 29 and to certain institutional investors in connection with a concurrent $75M private placement. AavantiBio is a privately held gene therapy company focused on transforming the lives of patients with Friedreich's ataxia and rare cardiomyopathies. Subject to the satisfaction or waiver of the other customary closing conditions, the closings of the merger agreement and the private placement are anticipated to take place on or around Friday, December 2. The combined company will focus on advancing a portfolio of neuromuscular and cardiac programs, led by SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne. Additional pipeline programs include AVB-202, a gene transfer candidate for the treatment of Friedreich's ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases.

ShowHide Related Items >><<
SLDB Solid Biosciences
$6.66 /

-0.03 (-0.45%)

SLDB Solid Biosciences
$6.66 /

-0.03 (-0.45%)

11/11/22 Barclays
Solid Biosciences price target raised to $8 from $2 at Barclays
11/10/22 Piper Sandler
Solid Biosciences price target lowered to $8 from $15 at Piper Sandler
10/17/22 SVB Securities
Solid Biosciences downgraded to Market Perform from Outperform at SVB Securities
10/03/22 Piper Sandler
Piper Sandler remains Neutral rated on Solid Biosciences, cuts target to $1
SLDB Solid Biosciences
$6.66 /

-0.03 (-0.45%)

Conference/Events
Intellia Therapeutics to participate in a conference call with JPMorgan » 10:45
12/01/22
12/01
10:45
12/01/22
10:45
NTLA

Intellia Therapeutics

$45.51 /

-5.82 (-11.34%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Cheng holds a conference call with President & CEO Leonard on December 1 at 11 am hosted by JPMorgan. Webcast Link

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

  • 01
    Dec
NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

NTLA Intellia Therapeutics
$45.51 /

-5.82 (-11.34%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 10:25
12/01/22
12/01
10:25
12/01/22
10:25
ACET

Adicet Bio

$18.31 /

+0.12 (+0.66%)

, ACLX

Arcellx

$20.08 /

+0.12 (+0.60%)

, ALLO

Allogene Therapeutics

$9.46 /

-0.38 (-3.86%)

, BMY

Bristol-Myers

$80.52 /

+0.33 (+0.41%)

, CELU

Celularity

$1.78 /

+0.08 (+4.71%)

, CLLS

Cellectis

$2.22 /

+0.01 (+0.45%)

, CRBU

Caribou Biosciences

$9.18 /

-0.145 (-1.55%)

, CRSP

Crispr Therapeutics

$54.83 /

+0.04 (+0.07%)

, DTIL

Precision BioSciences

$1.37 /

+0.01 (+0.74%)

, FATE

Fate Therapeutics

$20.93 /

+0.1 (+0.48%)

, GILD

Gilead

$88.72 /

+0.87 (+0.99%)

, GRCL

Gracell

$3.32 /

+0.07 (+2.15%)

, IPSC

Century Therapeutics

$10.45 /

-0.02 (-0.19%)

, JNJ

Johnson & Johnson

$178.00 /

+0.03 (+0.02%)

, LEGN

Legend Biotech

$51.29 /

-0.035 (-0.07%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.43 /

-0.03 (-0.35%)

, PSTX

Poseida Therapeutics

$4.63 /

+0.09 (+1.98%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.78 /

+0.08 (+4.71%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$88.72 /

+0.87 (+0.99%)

12/01/22 Oppenheimer
Gilead price target raised to $105 from $95 at Oppenheimer
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
GRCL Gracell
$3.32 /

+0.07 (+2.15%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

12/01/22 Jefferies
Horizon Therapeutics price target raised to $125 from $101 at Jefferies
12/01/22 Morgan Stanley
Johnson & Johnson price target raised to $178 from $170 at Morgan Stanley
11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.63 /

+0.09 (+1.98%)

NKTX Nkarta
$8.43 /

-0.03 (-0.35%)

MBIO Mustang Bio
/

+

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

DTIL Precision BioSciences
$1.37 /

+0.01 (+0.74%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

CLLS Cellectis
$2.22 /

+0.01 (+0.45%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

LEGN Legend Biotech
$51.29 /

-0.035 (-0.07%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

GRCL Gracell
$3.32 /

+0.07 (+2.15%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

FATE Fate Therapeutics
$20.93 /

+0.1 (+0.48%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CRBU Caribou Biosciences
$9.18 /

-0.145 (-1.55%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ALLO Allogene Therapeutics
$9.46 /

-0.38 (-3.86%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

ACET Adicet Bio
$18.31 /

+0.12 (+0.66%)

JNJ Johnson & Johnson
$178.00 /

+0.03 (+0.02%)

IPSC Century Therapeutics
$10.45 /

-0.02 (-0.19%)

GILD Gilead
$88.72 /

+0.87 (+0.99%)

CRSP Crispr Therapeutics
$54.83 /

+0.04 (+0.07%)

CELU Celularity
$1.78 /

+0.08 (+4.71%)

BMY Bristol-Myers
$80.52 /

+0.33 (+0.41%)

ACLX Arcellx
$20.08 /

+0.12 (+0.60%)

Hot Stocks
Syncona completes tender offer, acquisition of Applied Genetic Technologies » 07:19
12/01/22
12/01
07:19
12/01/22
07:19
AGTC

Applied Genetic

/

+

Applied Genetic…

Applied Genetic Technologies announced the successful completion of the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona. The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled to receive $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones. As a result of the merger, AGTC has become an indirect, wholly owned subsidiary of Syncona Limited. In the merger, each share of AGTC was cancelled and converted into the right to receive the same consideration, without interest, less any applicable withholding taxes, that was paid in the Offer. As of November 30, 2022, the common stock of AGTC will no longer be listed for trading on the Nasdaq Global Stock Market.

ShowHide Related Items >><<
AGTC Applied Genetic
/

+

AGTC Applied Genetic
/

+

10/24/22 Chardan
Applied Genetic downgraded to Neutral from Buy at Chardan
10/24/22 H.C. Wainwright
Applied Genetic downgraded to Neutral from Buy at H.C. Wainwright
10/24/22 Stifel
Applied Genetic downgraded to Hold from Buy at Stifel
10/04/22 Wells Fargo
Applied Genetic downgraded to Equal Weight from Overweight at Wells Fargo
  • 14
    Jul
  • 22
    Mar
AGTC Applied Genetic
/

+

Syndicate
Intellia Therapeutics 6.55M share Spot Secondary priced at $45.80 » 06:10
12/01/22
12/01
06:10
12/01/22
06:10
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

The deal size was…

The deal size was increased to $300M from $250M and priced at low end of $45.80-$47.80 range. Goldman Sachs is acting as sole book running manager for the offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Conference/Events
Intellia Therapeutics to participate in a conference call with JPMorgan » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Cheng holds a conference call with President & CEO Leonard on December 1 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Conference/Events
Oppenheimer emerging biotech analysts to hold analyst/industry conference call » 04:55
12/01/22
12/01
04:55
12/01/22
04:55
ACET

Adicet Bio

$18.20 /

+0.42 (+2.36%)

, ACLX

Arcellx

$19.90 /

+ (+0.00%)

, ALLO

Allogene Therapeutics

$9.84 /

+0.56 (+6.03%)

, BMY

Bristol-Myers

$80.19 /

+1.18 (+1.49%)

, CELU

Celularity

$1.71 /

+0.035 (+2.10%)

, CLLS

Cellectis

$2.22 /

+0.04 (+1.83%)

, CRBU

Caribou Biosciences

$9.33 /

+0.985 (+11.81%)

, CRSP

Crispr Therapeutics

$54.69 /

+1.78 (+3.36%)

, DTIL

Precision BioSciences

$1.36 /

+0.06 (+4.62%)

, FATE

Fate Therapeutics

$20.84 /

+1.07 (+5.41%)

, GILD

Gilead

$87.85 /

+2.09 (+2.44%)

, GRCL

Gracell

$3.28 /

+0.04 (+1.23%)

, IPSC

Century Therapeutics

$10.48 /

+0.14 (+1.35%)

, JNJ

Johnson & Johnson

$177.94 /

+1.895 (+1.08%)

, LEGN

Legend Biotech

$51.25 /

+2.64 (+5.43%)

, MBIO

Mustang Bio

/

+

, NKTX

Nkarta

$8.46 /

+0.365 (+4.51%)

, PSTX

Poseida Therapeutics

$4.54 /

+0.125 (+2.83%)

Emerging Biotechnology…

Emerging Biotechnology Analysts Breidenbach and Biegler, along with Drs. Rossi and Braunstein, discuss the evolving treatment landscapes in multiple myeloma and non-hodgkin lymphoma on an Analyst/Industry conference call to be held on December 1 at 11 am.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

09/21/22 JPMorgan
Adicet Bio initiated with Overweight, $23 target at JPMorgan
09/21/22 JPMorgan
Adicet Bio initiated with an Overweight at JPMorgan
03/30/22 SMBC Nikko
Adicet Bio initiated with an Outperform at SMBC Nikko
03/17/22 JMP Securities
Adicet Bio price target lowered to $21 from $30 at JMP Securities
ACLX Arcellx
$19.90 /

+ (+0.00%)

10/31/22 Guggenheim
Arcellx initiated with a Buy at Guggenheim
10/27/22 Needham
Arcellx initiated with a Buy at Needham
07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
07/20/22 Canaccord
Arcellx initiated with a Buy at Canaccord
ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

11/21/22 H.C. Wainwright
Allogene Therapeutics price target lowered to $29 from $43 at H.C. Wainwright
09/22/22 B. Riley
Allogene Therapeutics price target lowered to $18 from $21 at B. Riley
09/20/22 B. Riley
B. Riley replaces Allogene with Syndax as top pick for 2022
08/10/22 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

11/17/22 Credit Suisse
Bristol-Myers initiated with a Neutral at Credit Suisse
11/17/22 Morgan Stanley
Ventyx Biosciences initiated with an Overweight at Morgan Stanley
11/14/22 BMO Capital
CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
11/02/22 Evercore ISI
Evercore starts Legend Biotech with an Outperform on Carvykti potential
CELU Celularity
$1.71 /

+0.035 (+2.10%)

08/25/22 Alliance Global Partners
Celularity initiated with a Buy at Alliance Global Partners
08/23/22 Truist
Celularity price target lowered to $6 from $10 at Truist
06/22/22 H.C. Wainwright
Celularity initiated with a Buy at H.C. Wainwright
04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

08/18/22 Citi
Cellectis price target raised to $36 from $34 at Citi
05/18/22 Baird
Cellectis upgraded to Outperform at Baird on valuation 'backstop'
05/18/22 Baird
Cellectis upgraded to Outperform from Neutral at Baird
05/13/22 Barclays
Cellectis price target lowered to $7 from $9 at Barclays
CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

11/23/22 Citi
Caribou Biosciences price target lowered to $37 from $38 at Citi
08/29/22 Citi
Caribou Biosciences price target lowered to $38 from $39 at Citi
08/18/22 H.C. Wainwright
Caribou Biosciences price target lowered to $27 from $28 at H.C. Wainwright
05/12/22 Citi
Caribou Biosciences price target raised to $39 from $29 at Citi
CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

11/23/22 Citi
Crispr Therapeutics price target lowered to $63 from $83 at Citi
11/02/22 Barclays
Crispr Therapeutics price target lowered to $61 from $88 at Barclays
11/02/22 Credit Suisse
Crispr Therapeutics price target lowered to $78 from $90 at Credit Suisse
10/11/22 Morgan Stanley
Crispr Therapeutics initiated with an Underweight at Morgan Stanley
DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

11/10/22 H.C. Wainwright
Precision BioSciences price target lowered to $17 from $20 at H.C. Wainwright
06/16/22 BMO Capital
Precision BioSciences initiated with an Outperform at BMO Capital
06/09/22 William Blair
Precision BioSciences downgraded to Market Perform at William Blair
12/13/21 BTIG
Precision BioSciences price target raised to $20 from $16 at BTIG
FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

11/16/22 Citi
Fate Therapeutics price target lowered to $80 from $87 at Citi
11/04/22 Cantor Fitzgerald
Fate Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/10/22 Canaccord
Fate Therapeutics initiated with a Buy at Canaccord
08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
GILD Gilead
$87.85 /

+2.09 (+2.44%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
GRCL Gracell
$3.28 /

+0.04 (+1.23%)

09/22/22 Citi
Gracell initiated with a Buy at Citi
08/18/22 Wells Fargo
Gracell assumed with an Overweight at Wells Fargo
06/01/22 Cantor Fitzgerald
Gracell initiated with an Overweight at Cantor Fitzgerald
05/27/22 Piper Sandler
Gracell price target lowered to $10 from $25 at Piper Sandler
IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

11/14/22 H.C. Wainwright
Century Therapeutics price target lowered to $25 from $27 at H.C. Wainwright
11/11/22 Piper Sandler
Century Therapeutics price target raised to $24 at Piper after R&D day
10/31/22 Guggenheim
Century Therapeutics initiated with a Buy at Guggenheim
10/10/22 Canaccord
Century Therapeutics initiated with a Buy at Canaccord
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

11/30/22 Wells Fargo
Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
11/29/22 Craig-Hallum
Craig-Hallum sees potential for competing Apollo Endosurgery bids
11/28/22 Morgan Stanley
Genmab risk/reward favorable into arbitration ruling, says Morgan Stanley
11/17/22 Credit Suisse
Johnson & Johnson initiated with a Neutral at Credit Suisse
LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

11/01/22 Evercore ISI
Legend Biotech initiated with an Outperform at Evercore ISI
11/01/22 Cowen
Cowen starts Legend Biotech with an Outperform on Carvykti potential
11/01/22 Cowen
Legend Biotech initiated with an Outperform at Cowen
MBIO Mustang Bio
/

+

11/16/22 BTIG
Mustang Bio price target lowered to $4 from $8 at BTIG
08/17/22 BTIG
Bluebird's approval has positive read for Mustang Bio, says BTIG
07/14/22 B. Riley
Mustang Bio price target lowered to $4 from $5 at B. Riley
05/23/22 B. Riley
Mustang Bio price target lowered to $5 from $6 at B. Riley
NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

11/16/22 Mizuho
Nkarta price target lowered to $26 from $81 at Mizuho
11/10/22 Oppenheimer
Nkarta price target lowered to $36 from $50 at Oppenheimer
10/10/22 Canaccord
Nkarta initiated with a Buy at Canaccord
08/12/22 Cantor Fitzgerald
Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

11/11/22 BTIG
Poseida Therapeutics price target lowered to $14 from $20 at BTIG
08/09/22 Piper Sandler
Poseida Therapeutics price target raised to $11 from $9 at Piper Sandler
05/13/22 BTIG
Poseida Therapeutics price target lowered to $20 from $40 at BTIG
05/13/22 Piper Sandler
Poseida Therapeutics price target lowered to $9 from $19 at Piper Sandler
PSTX Poseida Therapeutics
$4.54 /

+0.125 (+2.83%)

NKTX Nkarta
$8.46 /

+0.365 (+4.51%)

MBIO Mustang Bio
/

+

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

DTIL Precision BioSciences
$1.36 /

+0.06 (+4.62%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

CLLS Cellectis
$2.22 /

+0.04 (+1.83%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

  • 04
    Aug
  • 27
    Jul
  • 17
    Jun
  • 26
    Apr
  • 04
    Feb
  • 16
    Dec
  • 08
    Dec
JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

LEGN Legend Biotech
$51.25 /

+2.64 (+5.43%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

GRCL Gracell
$3.28 /

+0.04 (+1.23%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

FATE Fate Therapeutics
$20.84 /

+1.07 (+5.41%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CRBU Caribou Biosciences
$9.33 /

+0.985 (+11.81%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ALLO Allogene Therapeutics
$9.84 /

+0.56 (+6.03%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

ACET Adicet Bio
$18.20 /

+0.42 (+2.36%)

JNJ Johnson & Johnson
$177.94 /

+1.895 (+1.08%)

IPSC Century Therapeutics
$10.48 /

+0.14 (+1.35%)

GILD Gilead
$87.85 /

+2.09 (+2.44%)

CRSP Crispr Therapeutics
$54.69 /

+1.78 (+3.36%)

CELU Celularity
$1.71 /

+0.035 (+2.10%)

BMY Bristol-Myers
$80.19 /

+1.18 (+1.49%)

ACLX Arcellx
$19.90 /

+ (+0.00%)

Wednesday
Syndicate
Intellia Therapeutics $250M Spot Secondary; price range $45.80-$47.80 » 17:50
11/30/22
11/30
17:50
11/30/22
17:50
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

Goldman Sachs & Co.…

Goldman Sachs & Co. is acting as the sole underwriter for the proposed offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

  • 01
    Dec
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Syndicate
Intellia Therapeutics announces $250M common stock offering » 16:41
11/30/22
11/30
16:41
11/30/22
16:41
NTLA

Intellia Therapeutics

$51.41 /

+3.44 (+7.17%)

Intellia Therapeutics…

Intellia Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its common stock. Goldman Sachs & Co. is acting as the sole underwriter for the proposed offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

11/14/22 Chardan
Intellia Therapeutics price target raised to $129 from $121 at Chardan
11/03/22 Chardan
Intellia Therapeutics price target lowered to $121 from $146 at Chardan
10/31/22 EF Hutton
Intellia Therapeutics initiated with a Buy at EF Hutton
10/11/22 Morgan Stanley
Intellia Therapeutics initiated with an Overweight at Morgan Stanley
NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

NTLA Intellia Therapeutics
$51.41 /

+3.44 (+7.17%)

Recommendations
Arrowhead price target lowered to $59 from $65 at B. Riley » 07:40
11/30/22
11/30
07:40
11/30/22
07:40
ARWR

Arrowhead

$29.98 /

+1.37 (+4.79%)

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani lowered the firm's price target on Arrowhead Pharmaceuticals to $59 from $65 and keeps a Buy rating on the shares. Arrowhead reported Q4 results and provided detailed updates to its RNAi therapeutics pipeline, constituting of 11 wholly owned and partnered clinical-stage programs that the company guided for expansion to a total 20 in 2025 while maintaining the goal of reaching one new cell type in every 12-18 months, Mamtani tells investors in a research note. "What's even more impressive is remarkably the lack of any failed/discontinued program based on clinical data generated," writes the analyst.

ShowHide Related Items >><<
ARWR Arrowhead
$29.98 /

+1.37 (+4.79%)

ARWR Arrowhead
$29.98 /

+1.37 (+4.79%)

11/09/22 Piper Sandler
Arrowhead price target lowered to $64 from $72 at Piper Sandler
09/09/22 Morgan Stanley
Arrowhead initiated with an Equal Weight at Morgan Stanley
08/05/22 Chardan
Arrowhead price target raised to $82 from $80 at Chardan
06/03/22 H.C. Wainwright
Arrowhead price target raised to $110 from $100 at H.C. Wainwright
ARWR Arrowhead
$29.98 /

+1.37 (+4.79%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.